ABSTRACT: MicroRNAs (miRNAs) are small non-coding RNAs that function to control many cellular processes by their ability to suppress expression of specific target genes. Tens to hundreds of target genes may be affected by one miRNA, thereby resulting in modulation of multiple pathways in any given cell type. Therefore, altered expression of miRNAs (i.e., during tissue development or in scenarios of disease or cellular stress) can have a profound impact on processes regulating cell differentiation, metabolism, proliferation, or apoptosis, for example. Over the past 5-10 years, thousands of reports have been published on miRNAs in cartilage and bone biology or disease, thus highlighting the significance of these non-coding RNAs in regulating skeletal development and homeostasis. For the purpose of this review, we will focus on miRNAs or miRNA families that have demonstrated function in vivo within the context of cartilage, bone or other orthopaedic-related tissues (excluding muscle). Specifically, we will discuss studies that have utilized miRNA transgenic mouse models or in vivo approaches to target a miRNA with the aim of altering conditions such as osteoarthritis, osteoporosis and bone fractures in rodents. We will not discuss miRNAs in the context skeletal cancers since this topic is worthy of a review of its own. Overall, we aim to provide a comprehensive description of where the field currently stands with respect to the therapeutic potential of specific miRNAs to treat orthopaedic conditions and current technologies to target and modify miRNA function in vivo. ß
MicroRNA (miRNAs) are small non-coding RNA molecules (typically 19-24 nucleotides in length) that function in RNA silencing and post-transcriptional regulation (suppression) of gene expression. 1 While the majority of miRNAs are located within the cell, some miRNAs, commonly known as circulating miRNA or extracellular miRNA, have also been detected outside the cell in the extracellular matrix, in various biological fluids, or in cell culture. 2 miRNAs were first discovered over 20 years ago in the nematode Caenorhabditis elegans with the identification of the developmental regulator lin-4. 3 Since then, thousands of miRNAs have been identified and investigated, with a wide distribution in animals, plants, and viruses. 4 MicroRNAs are ubiquitously expressed in different organisms, and many of them are phylogenetically conserved. 5 To date, over 28,000 miRNAs from various species are listed in the miRBase website (http://www.mirbase.org). Specifically, 2,588 mature miRNAs have been identified in humans and 1,915 mature miRNAs have been reported in mice.
With respect to miRNA biosynthesis, transcription of miRNA genes that are located either intergenically or intragenically is mediated primarily by RNA polymerase II in eukaryotes, although RNA polymerase III has also been shown to transcribe human miRNAs, particularly those interspersed among Alu repeats. [6] [7] [8] The primary transcript of a miRNA (pri-miRNA), which can range from several hundred to thousands of nucleotides in length, contains a hairpin structure that is cleaved and processed in the nucleus by the RNAse III enzyme, Drosha, and a cofactor protein that interacts with double-stranded RNA called DiGeorge syndrome critical region gene 8 (DGCR8). 9 The action of this microprocessor complex results in formation of a precursor miRNA (pre-miRNA) around 60-80 nucleotides long. 10 This pre-miRNA is trafficked from the nucleus to the cytoplasm by the GTP-dependent double stranded RNA binding protein, Exportin 5. 11 In the cytoplasm, the pre-miRNA is recognized by Dicer, an RNase III type endonuclease, and cleaved to $22 nucleotide long mature miRNA duplex. [12] [13] [14] The miRNA duplex consists of two RNA strands: A mature miRNA guide strand and a complementary passenger miRNA strand. After separation of two strands by helicases, the complementary passenger miRNA strand is typically degraded, while the mature miRNA guide strand is incorporated into a RNAinduced silencing complex (RISC) through interaction with Argonaute (Ago) proteins. However, in some cases, both miRNA strands are functional and can enter the RISC to interact with a specific site in the 3 0 UTR of a target mRNA resulting in either inhibition of translation and/or mRNA degradation. 15, 16 As reviewed by Eulalio et al., 17 the mechanisms by which miRNAs induce gene silencing is complex and still somewhat under debate. In cases where the miRNA is fully complementary to the mRNA, then endonucleolytic cleavage of target mRNAs by Argonaute proteins can occur. However a number of studies have shown that miRNAs with partial complementarity to target mRNAs can also regulate their decay by directing mRNAs to the general mRNA degradation machinery. To complicate matters, studies have also shown that the same miRNA can either repress translation or induce mRNA decay depending on the cell/tissue type, and that the structure of miRNA-mRNA duplexes can also influence whether translational inhibition or mRNA degradation is initiated. In addition, it has also been demonstrated that these gene silencing mechanisms may be coupled whereby translational suppression subsequently leads to mRNA degradation. 18 Regardless of the mechanism of miRNA-mediated gene suppression, the 6-8 nucleotide seed sequence of the miRNA binds with complete complementarity to a specific region in the 3 0 UTR of the target gene and is critical for miRNA function. Most commonly, partial pairing occurs between the remainder of the miRNA and the target gene. This lack of overall complementarity means that a single miRNA may target multiple mRNAs in a cell. Also, the level of suppression induced by miRNAs may be moderate compared to that of small interfering RNAs (siRNAs) which can bind to their targets with complete complementarity resulting in efficient knock-down of target gene expression via induction of mRNA degradation.
In terms of nomenclature, precursor miRNAs are designated "mir" while the mature miRNA is designated "miR" (i.e., mir-214; miR-214). A three letter prefix can also be added to the miRNA name to specify species of origin (i.e., hsa-miR-214 or mmu-miR-214 for human and mouse, respectively). The mature strand may be defined further by stating whether it is derived from the 5 0 or 3 0 strand of the mature miRNA duplex (i.e., miR-214-5p; miR-214-3p). In older miRNA literature, an asterisk was often used to define the minor, non-functional miRNA strand (i.e., miR-138-5p; miR-138 Ã ) In addition, miRNAs that differ by only one or two nucleotides are designated by lower case letters (e.g., miR-146a, miR-146b). Finally, miRNAs that have identical mature strand sequences but are located at different sites in the genome are indicated by a dashnumber suffix (i.e., miR-181a-1 and miR-181a-2).
Although miRNAs account for only 1-5% of human genome, 19 up to 60% of protein-coding genes are regulated by miRNAs at the post-transcriptional level. 20 Many miRNAs are transcribed as independent transcriptional units, having their own promoter and other regulatory elements. However, some miRNAs are clustered together in a genome (from 35% in the human genome to 46% in Danio rerio genome). These clustered genes can form polycistronic transcripts that contain several miRNAs. 21, 22 In addition, miRNAs can be found in either introns or exons of a host gene. Such intragenic miRNAs are often co-transcribed and co-expressed from the host promoters 23 whereas intrergenic miRNA genes or clusters can be expressed under control of their own promoters. 24 MiRNA expression in vivo is tightly regulated via several mechanisms including DNA methylation, histone deacetylation, DNA copy alteration, and gene mutations affecting proteins involved in miRNA processing and maturation. 25 miRNA expression can also undergo intrinsic regulation which involves alteration in the RNA sequence and/or structure that affect the maturation and turnover of mature miRNAs, including single nucleotide polymorphisms, miRNA tailing, RNA editing, and RNA methylation 16 ( Fig. 1) . Single nucleotide polymorphisms (SNPs) within miRNA genes can affect their specificity to target mRNAs. 26 RNA tailing, by Lin28 and the terminal uridylyl transferase (TUT) family of enzymes, involves the addition of nucleotides to the 3 0 end of RNA, thereby modifying its expression. [27] [28] [29] RNA editing occurs by the conversion of adenosine to inosine through the adenosine deaminase acting on RNA (ADAR) family of enzymes. 30, 31 These latter two processes can occur in pri-miRNA transcripts and can cause insufficient Dicer processing. 32 Also, RNA methylation can occur through Omethylation of the 5 0 end of pre-miRNA by an RNA methyltransferase, which can also disrupt Dicer processing. 33 Identification of real miRNA targets is a challenging step necessary for understanding their function. In silico approaches are based on assumptive miRNA target recognition which requires conserved pairing to the 5 0 region of the miRNA centered on nucleotides 2-7 of the seed sequence. Several miRNA target prediction programs based on the identification of matched sites within 3 0 UTRs of targeted mRNAs are available. 34 In a "wet" approach (miRNA crosslinking and immunoprecipitation; miR-CLIP), pre-miRNAs are modified with psoralen and biotin in order to capture intracellular targets. 35 Upon ultraviolet light exposure to living cells, covalent bonds are formed between proteins and nucleic acids that are in close proximity. 36 The cells are then lysed, and the protein of interest is isolated via immunoprecipitation. In order to allow for sequence specific priming of reverse transcription, RNA adapters are ligated to the 3 0 ends, while radiolabeled phosphates are transferred to the 5 0 ends of the RNA fragments. The RNA-protein complexes are then separated from free RNA and protein digestion is performed. This step leaves a peptide at the cross-link site, allowing for the identification of the cross-linked nucleotide. 37 After ligating RNA linkers to the RNA 5 0 ends, cDNA is synthesized via RT-PCR. High throughput CLIP data can be combined with a bioinformatics approach to identify miRNA targets. 38 MicroRNAs localize to different subcellular compartments including the mitochondria, endoplasmic reticulum, processing bodies (PBs), nucleus, and nucleolus. 39 Mature miRNAs can also be secreted from cells via exosomes. 40, 41 Localization and distribution of miRNAs can be influenced by protein modifications and the availability of AGO family members and other non-AGO miRNA-binding proteins. 39 PBs are sites of mRNA surveillance that are enriched with AGO family members and other RNA decay factors. 42 The function of miRNAs in PBs involves the decay and storage of miRNA targets and other RNA decay factors. 43 AGO family members, as well as Dicer, localize in the endoplasmic reticulum (ER) and multivesicular bodies. 44 miRNA-mediated post-transcriptional regulation
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MCALINDEN AND IM of gene expression occurs in the ER. 45 Mature miRNAs and miRISC components also exist within the nucleus and nucleolus. 46, 47 Nuclear miRNAs are involved in epigenetic regulation through silencing or activating gene promoters. 48 The nucleolus is involved in ribosome biogenesis, cell cycle control, and signaling. 49 miRNAs found in the nucleolus are actively trafficked to the cytoplasm in a manner dependent on exportin1. 50 Several miRNAs and associated miRISC components also exist within the mitochondria. 51 miRNAs localize to the mitochondria to regulate mitochondriaspecific mRNA targets. 52 Several functions of these mito-miRNAs have been proposed, including regulation of ubiquitination, apoptosis, and biological pathways such as transforming growth factor, Wnt, p53, and cell cycle. 53 When it became evident that miRNAs play significant roles in regulating various biological pathways in normal growth, development and metabolism, an interest in the role of aberrant miRNA expression in disease pathogenesis has increased. 54 The first study to link miRNAs with pathology showed an association with abnormal miRNA expression in chronic lymphocytic leukaemia. 55 In addition to malignancies, dysregulation of miRNAs appears to play a role in many other chronic disease processes including cardiovascular disease, epilepsy, asthma, and diabetes. In this review, we will discuss a number of reports from the published literature suggesting a link between miRNAs and various human orthopaedic conditions. Given that many thousands of studies (in vitro and in vivobased) have now been published on the involvement of miRNAs in the biology and disease of cartilage, bone and other orthopaedic-related tissues, we will focus our attention on potential miRNA function in vivo. This includes miRNA transgenic mouse models or in vivo targeting approaches to modulate miRNA expression that have shown subsequent effects on altering skeletal development or disease. The potential therapeutic application of some of these miRNAs will also be discussed in addition to perspectives on the future of miRNA research in the field of orthopaedics.
MiRNAs REGULATING SKELETAL DEVELOPMENT AND HOMEOSTASIS-EVIDENCE FROM HUMAN CLINICAL STUDIES AND MOUSE MODELS
Findings from clinical reports reveals the importance of miRNAs in regulating human skeletal development. One study reported that mutation within the 3 0 UTR of HDAC6 disrupts the miR-433 binding site, resulting in a dominant X-linked chondrodysplasia. 56 Another study reported that deletion or duplication of MIR17HG, encoding the miR-17 $92 cluster, results in human skeletal defects including short stature, abnormalities in digit formation, and facial features. 57, 58 Also, mice harboring a targeted deletion of the miR-17 $ 92 cluster phenocopied several features of the affected humans. 57 However, the mechanism by which the miR-17 $ 92 cluster regulates skeletal development has not yet been fully elucidated Further associations between miRNAs and human skeletal development have been suggested from reports on patients with deletions or a translocation within chromosome 1q24 resulting in various skeletal abnormalities. [59] [60] [61] [62] [63] [64] Recently, Ashraf et al. reported two additional patients with microdeletions in 1q24q25 that display similar skeletal abnormalities as reported previously (i.e., short stature, brachydactyly, and facial dysmorphism). 65 The deletion mutation in one of these patients narrowed down the critical region causing these skeletal defects to that encoding dynamin-3 (DNM3) and two miRNAs located within intron 14 of this gene (miR-199a and miR-214). Interestingly, a study by Watanabe et al. showed skeletal defects in mice devoid of the long non-coding RNA, Dnm3os, an antisense transcript in intron 14 of Dnm3 that harbors both miR-199a and miR-214. 66 After birth, Dnm3os homozygous null pups displayed skeletal defects including short stature, cranial deformity, hypoplasia of the dorsal vertebrae, and osteopenia. Importantly, expression of dynamin-3 (that is known to play roles in mitochondrial fission and endocytosis, e.g.), was not affected in Dnm3os homozygous knockout mice. However, expression of Dnmt3os and miR-214 were not detectable, while expression of miR-199a was significantly lower in homozygous pups. The fact that some miR-199a expression was still detected is because another miR-199a subtype is located elsewhere in the genome. Together, these human and mouse studies strongly suggest that miR-199a and miR-214 may function as important regulators of bone and cartilage development and homeostasis. While no specific mechanisms were determined for these miRNAs in these studies, other reports have been published on the functional roles of miR-199a and miR-214 in various in vivo and in vitro systems. This will be discussed more in the following sections.
In vivo modulation of proteins involved in miRNA processing (i.e., Dicer, Drosha, Dgcr8) highlights the importance of miRNA function in controlling skeletal development and homeostasis. Striking phenotypes were found in mice where the pre-miRNA processing enzyme Dicer was deleted either early during bone development in osteoprogenitors (Col1a1-Cre) or later in mature osteoblasts (Osteocalcin-Cre). Fetal survival after E14.5 was compromised in the Col1a1-Cre Dicer knock-out embryos as was bone mineralization. However, increased bone mass was found in OsteocalcinCre-driven Dicer knock-out mice by 2 months of age. 67 In addition, osteoclast-specific Dicer deficiency resulted in defects in bone resorption. 68 A similar bone phenotype was also found in mice with osteoclastspecific deletion of Dgcr8, which is a critical component of the pri-miRNA processing complex via its interaction with Drosha. 69 A recent study showed that deletion of Dgcr8 in osteoprogenitors (Col1a1-Cre) resulted in enhanced bone formation due, in part, to downregulation of miR-22 and subsequent upregulation of osteocalcin transcripts. 70 With respect to cartilage tissue, Kobayashi et al. reported a severe growth retardation phenotype in mice devoid of Dicer, in type II collagen-producing cells (Col2a1-Cre; Dicer f/f ). 71 Conditional deletion of the pri-miRNA processing enzyme, Drosha, in lubricin (Prg4)-expressing cells resulted in increased cell death and mild OA effects in cartilage, but interestingly only in male mice. 72 miR-140 is known to be highly expressed in chondrocytes and is one of the most studied miRNAs in cartilage biology. Transgenic mice devoid of miR-140 have been generated by two independent groups. 73, 74 Both laboratories reported similar phenotypes whereby homozygous knock-out mice displayed relatively mild dwarfism and craniofacial defects. Kobayashi's group extended their studies to examine post-natal articular cartilage in miR-140 null mice and found that these mice displayed accelerated ECM degradation compared to control mice. 74 Interestingly, when miR-140 was over-expressed in Col2a1-expressing cells, these mice appeared to be somewhat protected from proteoglycan and type II collagen loss following antigen-induced arthritis (AIA), an arthritic injury model that results in severe inflammation within the synovial joint. These findings, together with other reports that miR-140 has anti-catabolic or pro-anabolic effects in chondrocytes [74] [75] [76] [77] [78] [79] suggests that targeting this miRNA could be a promising therapeutic approach to treat inflammation-induced cartilage degradation. Interestingly, a recent study showed that exosomes derived from rat synovial mesenchymal stem cells (SMSCs) and engineered to over-express miR-140 (SMSC-140-Exos) are chondroprotective. 80 Specifically, SMSC-140-Exos or control exosomes were injected into rat knee joints following induction of OA via transection of the medial collateral ligament, the medial meniscus and anterior cruciate ligament. It was presumed that exosomes were taken up by articular chondrocytes in vivo, resulting in miR-140 transfer to these cells and a dramatic decrease in articular cartilage degradation following joint injury. Further studies utilizing other animal models of OA and approaches to properly monitor transfer of miRNAs to chondrocytes via exosomes in vivo will be required. Another recent study has also shown a chondroprotective effect in rats following a single intra-articular injection of miR-140 agomirs following induction of OA. 81 These studies strongly suggest that miR-140 could be a promising therapeutic target to treat OA. miR-146a is responsive to pro-inflammatory cytokines in chondrocytes and elevated expression levels of this miRNA have been identified in OA cartilage or plasma from OA patients. [82] [83] [84] Contradictory results have been published suggesting either beneficial [85] [86] [87] [88] or adverse effects 84, 89 of miR-146a on chondrocytes. It was shown that in vivo delivery of double-stranded miR-146a mimics could inhibit osteoclastogenesis and bone destruction in an inflammatory model of collagen-induced arthritis. 90 Studies utilizing ex vivo intervertebral disc (IVD) organ cultures established from miR-146a knock-out (KO) mice suggest that this miRNA may function to attenuate the inflammatory 36 MCALINDEN AND IM cytokine response, thereby suppressing IVD degeneration. 85 However, in contrast, a recent study suggests beneficial effects of miR-146a inhibition in articular cartilage. 91 Here, miR-146a KO mice appeared to be protected from spontaneous or surgically-induced OA and that intra-articular injection of lentiviruses expressing an inhibitor of miR-146a attenuated articular cartilage degradation following OA induction. Further studies are needed to accurately determine why this miRNA may function differently in IV disc cells compared to articular cartilage cells. Also worth considering is the potential of inducing different effects when a miRNA mimic is over-expressed compared to a lentiviral construct expressing the precursor form of the same miRNA.
According to the published literature, no other miRNA null or over-expression mouse models have been reported that display a cartilage phenotype. However, it may be that other models have been generated, but no skeletal phenotype was found or even looked for. In fact, many miRNA KO mice exist that display either a mild or no phenotype. 92 These findings are likely due to the high degree of redundancy that exist among miRNAs. Also, in many cases, phenotypes in miRNA KO or over-expressing mice are only apparent when animals are subject to stress or injury. 93 This appears to be the case for the miR-146a KO mouse model mentioned above whereby a phenotype was only recognized in these mice following aging or induction of injury. This finding should be taken into consideration when studying other miRNA KO models to determine potential effects on skeletal tissue homeostasis.
With respect to miRNA over-expression in vivo, an effective approach utilizing a Cre-loxP-mediated dual fluorescence expression system has been reported. 94 Here, a fluorescent signal switch from green to red enables real time monitoring of the small non-coding RNA in vivo. More recently, this approach has been utilized and validated in cartilage tissue by effectively over-expressing a pre-miR-365-containing transgene in Col2a1-producing murine chondrocytes in vivo. 95 This approach will prove to be useful for studying the in vivo effects of miRNA over-expression in cartilage or other orthopaedic connective tissues of interest.
In a recent study, microarray analysis identified a number of miRNAs that were differentially expressed in bone marrow-derived stem/stromal cells (BMSCs) from young (3 month) and old (18 month) mice. 96 The rationale for this work was based on the knowledge that BMSCs from aging mice or humans are known to have less osteogenic and more adipogenic potential when compared to "young" BMSCs. In this report, miR-188 was found to be significantly increased ($30-fold) in BMSCs from aged mice compared to cells from younger animals; this age-related trend was also confirmed in human BMSCs. Importantly, global deletion of miR-188 in mice resulted in significant reduction of age-associated bone loss and fat accumulation in the bone marrow. Conversely, when miR-188 was over-expressed in osterix-expressing osteoprogenitors, aged mice exhibited accelerated bone marrow fat accumulation and bone loss. This study is a good example of how KO or over-expression of one miRNA in mice can generate a significant skeletal phenotype. In terms of mechanism, it was found that the function of miR-188 to target both HDAC9 and RICTOR was partly responsible for the phenotype. Importantly, the clinical significance of this work was apparent since the bone/adipose phenotype could be reproduced in WT mice following aptamer-based delivery of either a miR-188 mimic or antagomir specifically in BMSCs. This and other delivery methods to activate or inhibit miRNA function in vivo will be discussed later in this review. Overall, this study has generated new, important information on a miRNA-based mechanism that controls the age-related switch between osteogenesis and adipogenesis. Therefore, miR-188 inhibition via antagomir delivery may represent a potential therapeutic strategy for age-related bone loss.
Transgenic mice expressing miR-206 under control of the a1(I) collagen promoter have also been generated and develop low bone mass due to impaired osteoblast differentiation. 97 This group identified miR-206, previously viewed as a muscle-specific miRNA, to be one of a number of miRNAs down-regulated during BMP-2-induced osteoblastic differentiation of C2C12 cells. Connexin-43 (Cx-43) was found to be one target of this miRNA and, as expected, levels of Cx-43 were found to be lower in bones of miR-206 transgenic mice. These studies suggest that levels of miR-206 need to remain low to permit efficient osteoblast differentiation and bone formation.
A recent study utilizing miR-21 global knock-out mice has uncovered an osteo-protective effect of miR-21 inactivation in osteoporosis. 98 While skeletal development was normal in these mice, miR-21 deficiency was found to promote trabecular bone mass accrual physiologically. Interestingly, in pathological states, the protection of bone mass was prominent in miR-21 À/À mice compared to controls. In vitro studies have shown that miR-21 can promote both osteogenesis and osteoclastogenesis. 99, 100 However, these in vivo findings apparently support a pro-osteoclastic role for miR-21.
A study by Wei et al. identified increased expression of the miR-34 family (miRs-34a,b,c) during osteoblastic differentiation of mouse calvarial cells. 101 To determine the in vivo effects of these miRNAs, a gain-offunction mouse model was generated to over-express miR-34c under control of the a1(I) collagen promoter.
Conditional miR-34abc
OsbÀ/À null mice were also generated to knock-out the miR-34 family by crossing with a1(I) collagen-Cre transgenic mice. Interestingly, over-expression of miR-34c in vivo resulted in a low bone mass phenotype in mouse vertebrae at 3 months of age while conditional deletion of miR-34abc increased vertebral bone mass at 3 months. Mechanisti-
cally, the in vivo findings showed that the effects of miR-34 on osteoblasts did not appear to affect osteoclast number or bone resorption, providing further evidence that bone formation and resorption need not be coupled in vivo. This study did not show if bone mass from other sites such as the limbs were also affected in their mouse models.
However, contradictory results have been reported via generation of an osteoclast-specific miR-34a gainof-function mouse model which was shown to suppress osteoclastogenesis and bone resorption, thereby protecting against bone loss due to ovariectomy-induced osteoporosis as well as preventing bone metastases of breast and skin cancers. 102 This data suggests functional divergence between members of the miR-34 family and/or highlights that modulation of miRNAs in a specific cell type (i.e., over-expressing a miRNA in osteoblast versus osteoclast cells) may have different biological outcomes. These findings are important when considering therapeutic strategies to target miRNAs in vivo.
With respect to OA, a recent study showed that lentiviral delivery of anti-miR-34a could ameliorate the progression of OA following anterior cruciate ligament transection and medial meniscus resection in rats. 103 This study, and a previous in vitro-related study, 104 showed that silencing miR-34a could results in reduced chondrocyte apoptosis.
O T H E R F U N C T I O N A L m i R N A s W I T H T H E R A P E U T I C P O T E N T I A L T O T R E A T ORTHOPAEDIC CONDITIONS
There are now many published studies reporting functional roles of miRNAs in regulating development or homeostasis of cartilage and bone using in vitro and/or in vivo approaches. In this section, we will focus on some key miRNAs where function has been validated following approaches to activate or inhibit the miRNA of interest in vivo. The therapeutic potential of many of the miRNAs discussed in this review is also summarized in Table 1 .
A number of studies have revealed that miR-214 functions as an inhibitor of bone formation, albeit via different mechanisms. [105] [106] [107] [108] Importantly, work by Wang et al. demonstrated that osteoblast-targeted delivery of miR-214 antagomir in mice attenuated the bone loss induced in osteocalcin conditional miR-214 gain-of-function (GOF) mice as well as in ovariecomtized (OVX) mice. 105 This study also showed that miR-214 can regulate bone formation, in part, by targeting the transcription factor, ATF4. Interestingly, in another study, miR-214 was shown to promote osteoclastogenesis in vitro and, when over-expressed in osteoclasts in transgenic mice (Acp5-miR-214-TG), a low bone mass phenotype was observed. 109 Targeting of Pten by miR-214 was identified as one of the mechanisms by which this miRNA regulates osteoclastogenesis. In support of these findings, another group also reported bone loss in a different osteoclast-specific miR-214 GOF mouse model (Ctsk-miR-214-TG) and that this phenotype was rescued by treatment of osteoclast-targeted miR-214 antagomirs. 110 These antagomirs could also attenuate bone loss in aged OVX mice as well. A particularly exciting finding from this work, and another recent study 111 was that osteoclast-derived exosomes enriched in miR-214 could apparently be transferred to osteoblasts to inhibit bone formation. This data proposes the existence of miRNA-mediated cross-talk between osteoclasts and osteoblasts via exosomes to control bone homeostasis. Taken together, all of the aforementioned studies strongly suggest that inhibition of miR-214 in either osteoblasts or osteoclasts may be an effective therapeutic strategy to treat skeletal disorders involving reduced bone formation.
There have been a number of reports on the function of the miR-29 family in regulating skeletal cell differentiation and homeostasis. For example, miR-29a appears to enhance bone formation and mineralization via modulation of Wnt signaling. [112] [113] [114] Recently, IL-32ɣ was found to stimulate bone formation by increasing miR-29a levels. 115 Another report showed that in vivo administration of miR-29a, via tail vein injection of lentiviruses expressing pre-miRNA29a, could attenuate the effects of glucocorticoidinduced bone loss. 116 In terms of mechanism, miR-29a was found to modulate Wnt signaling and enhance expression of Runx2 and IGF-1 in bone. In addition, Ko et al. reported a similar function for miR-29a in mitigating glucocorticoid-induced bone loss by rescuing Runx2 acetylation. 117 These studies suggest that activation of miR-29a could be a therapeutic strategy to treat bone loss induced by glucocorticoid treatment. However, a recent study showed that miR-29 can also promote murine osteoclastogenesis 118 thereby casting some doubt on the potential long-term efficacy of miR29a mimics to treat low bone mass conditions. Expression of miR-29a decreases during MSC chondrogenesis and SOX9 was also found to repress expression of this miRNA. 119, 120 This suggests that miR-29a plays an inhibitory role in chondrogenesis induction, unlike its apparent role in enhancing bone formation. While miR-29 levels are altered in OA and in response to inflammatory cytokines, 79 the functional of role of miR-29 in regulating cartilage homeostasis is currently not known. However, a recent study has demonstrated that decreased levels of miR-29a were associated with synovial fibrosis in human OA knees. In addition, intra-articular administration of lentiviruses expressing pre-miR-29a, following collagenase-induced knee joint aggravation in mice, ameliorated synovial angiogenesis and fibrosis thereby slowing down joint destruction. 121 One mechanism by which miR-29a is predicted to modulate synovitis is by suppression of VEGF. This study suggests a potential therapeutic advantage to over-expressing miR-29a in OA knee joints. Interestingly, miR-29a replacement therapy was recently suggested as a potential strategy to treat tendinopathies. 122 In this study, it was found that decreased levels of miR-29a, induced in part by IL-33 following tendon injury, resulted in increased levels of type III collagen, a matrix component known to reduce tendon tensile strength and early tendon failure. In human tenocytes, over-expression of miR-29a decreased COL3 mRNA and protein levels, supporting the claim that miR-29a mimic delivery may be an attractive approach to control levels of type III collagen expression during tendon healing.
miR-2861 was found to enhance osteoblast differentiation and bone formation, in part, by targeting HDAC5. 123 Silencing of miR-2861 in vivo via administration of antagomir-2861 resulted in decreased bone mass in mice in addition to enhanced HDAC5 and reduced Runx2 protein expression. The murine in vivo studies correlated with the human findings whereby decreased levels of miR-2861 were found in two related patients with primary osteoporosis. 123 These studies suggest that activation of miR-2861 via mimics could be another strategy to treat low bone mass conditions.
Mechanosensitive miRNAs were identified in a study utilizing cyclic mechanical stretch (CMS) to induce osteoblast differentiation of the human cell line hFOB 1.19. 124 Expression of miR-103a was found to decrease during 3 days of CMS-induced differentiation while its expression was increased in femurs from an osteoporosis mouse model generated by hindlimbunloading (HU). In vitro and in vivo assays showed that Runx2 is a target of miR-103a, further supporting a potential role in regulating bone formation. Importantly, administration of antagomir-103a to HU and control mice over the period of 1 month partly rescued the osteoporosis phenotype caused by mechanical unloading. This study revealed that inhibition of this mechanosensitive miRNA could be a potential therapeutic strategy to enhance anabolic bone formation in osteoporosis-like scenarios caused by pathological mechanical loading.
miR-365 was identified as a mechanosensitive miRNA in chondrocytes and was found to stimulate hypertrophic differentiation of these cells by targeting HDAC4. 125 Follow-up studies by the same group showed that miR-365 is upregulated in articular chondrocytes by cyclic loading or IL-1b stimulation. 126 They also showed that, compared to control tissue, miR-365 levels were higher in cartilage from a rat OA model as well as in human cartilage OA specimens. Also, over-expression of miR-365 in chondrocytes activated catabolic/hypertrophic gene expression (COL10A1, MMP13) suggesting that elevated levels of this miRNA are potentially deleterious to cartilage. This group has generated miR-365 transgenic mice to permit conditional over-expression of this miRNA in cartilage tissue. 95 Therefore the in vivo function and the therapeutic potential of targeting miR-365 as a means to treat OA remains to be determined. miR-483 has been identified in a number of independent studies to be upregulated in human or mouse OA cartilage. [127] [128] [129] [130] This miRNA is located within the insulin-like growth factor 2 (IGF2) gene and studies in our laboratory have shown that it is differentially expressed during human chondrocyte differentiation (lower levels in hypertrophic chondrocytes compared to chondro-progenitor cells). 131 Subsequent work in our group has recently shown that over-expression of pre-miR-483 in primary human BMSCs inhibits early chondrogenesis, in part, by targeting SMAD4. 132 However, when miR-483-5p mimics were over-expressed in primary bovine chondrocytes, increased proteoglycan and collagen synthesis was reported. 130 This effect was suggested to be due, in part, to suppression of MAPK signaling. Together, these studies suggest that the function of miR-483 in chondrocytes may vary depending on the differentiation status of the cell. Recent in vivo data showed that miR-483 over-expression in murine articular cartilage resulted in enhanced cartilage degradation, whereas intra-articular delivery of antago-miR-483-5p inhibited OA progression by modulating matrilin-3 and TIMP2. 133 The anabolic versus catabolic effects of miR-483-5p over-expression reported by Yang et al. 130 and Wang et al. 133 respectively may be due to the fact that one study was performed on chondrocytes isolated from cartilage tissue in vitro while the other involved modulation of miR-483-5p in chondrocytes in vivo, embedded within their natural matrix environment. Studies in our group have shown that members of the miR-181 family are expressed in chondrocytes from developing human cartilage, but more so in hypertrophic chondrocytes. 131 This differential expression pattern was also confirmed in MSC chondrogenesis assays in vitro 134 and suggests a potential role for miR-181 in regulating terminal hypertrophic differentiation or endochondral ossification. With respect to chondrocyte homeostasis, miR-181a/b has been shown to decrease expression of aggrecan and CCN1 135 while in other studies it was reported to promote chondrocyte catabolism and apoptosis.
136-138 Nakamura et al. found higher levels of miR-181a in OA facet joint cartilage compared to control specimens and showed that injection of miR-181a mimics into the facet joints of rats induced cartilage degradation. 138 Song et al. reported higher levels of miR-181b in mouse OA articular cartilage (induced by joint destabilization surgery) and that inhibition of miR-181b by intraarticular injection of miR-181b antagomirs following surgery apparently attenuated the effects of OA. 137 However, Tu et al. reported decreased levels of the miR-181 family (miR-181a/b/c/d) in human OA articular cartilage tissue. 139 More studies are needed to determine the function of miR-181 in regulating knee/ hip joint articular cartilage homeostasis.
miR-181a expression has been to shown to increase during in vitro osteogenesis and that its over-expression promotes osteoblast differentiation. 140 Other stud-
ies point to the fact that miR-181a may also function to negatively regulate osteoclast survival. 141, 142 Therefore, further work is required to evaluate the function of miR-181 on bone homeostasis in vivo. The McAlinden lab is currently analyzing miR-181ab knock-out and knock-in mice to determine the role of these miRNAs in regulating skeletal differentiation and post-natal maintenance in vivo.
miR-138 has been reported to inhibit MSC osteogenesis 143, 144 and that miR-138 knock-down could enhance bone formation in vivo. Specifically, Eskildsen et al. transfected human MSCs with constructs expressing pre-miR-138 or antimiR-138 and transferred these, via a hydroxyapatite-based scaffold, to subcutaneous regions in immunocompromised mice. 144 Eight weeks following implantation, enhanced osteoblast differentiation and bone formation was reported in the antimiR-138 group. Yan et al. generated cell sheets derived from bone marrow-derived MSCs transfected with or without antimiR-138, wrapped these sheets around freeze-dried bone allografts which were then implanted subcutaneously in immunocompromised mice. Increased mineralization of existing bone as well as formation of new bone was found in the cell sheet constructs expressing antimiR-138 compared to the control group. 145 In other systems, miR-138 has been found to inhibit cell differentiation 146, 147 and has also been reported to induce pluripotency by regulating p53. 148 Also, higher levels of miR-138 are expressed in de-differentiated chondrocytes compared to differentiated chondrocytes. 149 Therefore, it appears that miR-138 levels must be low enough to permit cell differentiation toward a desired lineage. Therapeutic strategies to inhibit this miRNA with the goal of enhancing bone (or cartilage) formation should be done in conjunction with MSC/progenitor cells since levels of miR-138 will be high enough to be inhibited, unlike in differentiated cells where endogenous levels are likely too low to consider inhibition.
Similar to miR-138, miR-31 levels have also been found to decrease during MSC osteogenesis 150 and its over-expression inhibits osteoblast differentiation. 151, 152 Interestingly, elevated levels of miR-31 were identified in the plasma of elderly and osteoporosis patients. 152 It was also suggested in this study that a major source of miR-31 in the plasma is from microvesicles (MVs) secreted from senescent endothelial cells and that miR-31-containing MVs can be taken up by MSCs to inhibit osteogenesis. On the other hand, miR-31 up-regulation has been reported during osteoclast development and that miR-31 inhibition disrupted osteoclast formation by targeting RhoA. 153 These findings suggest a potential therapeutic strategy to enhance bone formation via anti-miR-31 delivery strategies to MSCs. This has indeed been demonstrated in three bone tissue engineering-based studies by the same group. [154] [155] [156] In vivo delivery of miR-210-expressing lentiviral constructs into the knee joints of rats following induction of OA (via anterior cruciate ligament transection) apparently resulted in anti-apoptotic and anti-inflammatory effects in the joint cavity. 157 It was suggested that miR-210 functioned by targeting death receptor 6 (DR6) and inhibiting NF-kB signaling. However, a critical control (lentiviral injection expressing scrambled control miRNA) appears to be missing from this study and no joint histological analyses were carried out to determine long-term effects on potential attenuation of OA by miR-210. Interestingly, injection of double-stranded miR-210, with atelocollagen, into the knee joints of rats following injury to the avascular medial meniscus or anterior cruciate ligament resulted in accelerated healing of these tissues. 158, 159 The mechanism of healing is not known, although increased expression levels of VEGF, FGF-2, and collagens were noted in the treatment groups. Although no in vivo studies have been performed, studies suggest that miR-210 may also function to promote osteoblast differentiation. 160, 161 A number of reports have suggested beneficial effects of targeting miRNAs to promote repair of bone fractures. Murata et al. found that systemic or local inhibition of miR-92a enhanced fracture healing in young mice by promoting angiogenesis. 162 Lee et al. found that murine tail vein injection of miR-29b-expression plasmids enclosed in microbubbles at 2 weeks post femoral fracture, resulted in enhanced endochondral bone healing. 163 Further injections at 3 weeks post surgery did not show an additive effect, but rather interfered with the healing process. Yoshizuka et al. performed femoral transverse fractures in rats followed by cauterization of the periosteum and found enhanced bone healing following delivery of miR-222 inhibitors to the fracture site. 164 Inhibition of this miRNA apparently enhanced osteogenesis, chondrogenesis as well as angiogenesis. Interestingly, miR-222 inhibition apparently enhanced progression of cartilage degradation and OA following DMM surgery, while delivery of miR-222 via lentiviral constructs was chondro-protective. 165 Finally, another study has shown potential therapeutic effects of administering miR-142 agomirs to the fracture site of aged mice. 166 This study also suggested that one mechanism by which miR-142 promotes osteoblast activity and matrix mineralization is by targeting a gene encoding WWdomain-containing E3 ubiquitin protein ligase 1.
MiRNAs ASSOCIATED WITH SKELETAL DISEASE AND OTHER ORTHOPAEDIC CONDITIONS
Significant efforts have focused on identifying changes in expression levels of tissue-based or circulating miRNAs with the goal of identifying new disease mechanisms or disease-associated biomarkers. Recently published reviews provide detailed information on many studies that have discovered differentiallyexpressed miRNAs in OA, osteoporosis, or other bone defects. In this section, we will focus attention on miRNAs associated with skeletal/orthopaedic condi-
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Many differentially-expressed miRNAs have been identified in either cartilage tissue or serum from human OA patients compared to non-diseased control samples. 25, 167, 168 More recently, differential expression of miRNAs in exosomes from synovial fluid of OA patients has been reported and that these changes are gender-specific. 169 Contradictory results exist for miR-140 expression patterns in OA whereby some reports have shown decreased levels 75, 77, 127, 170 while another showed increased expression in OA cartilage. 171 These contrasting findings may be explained by the heterogeneous nature of human OA cartilage samples analyzed by independent research groups. For example, cartilage specimens of a similar OA grade may contain different ratios of chondrocytes actively attempting to repair the extracellular matrix (ECM) compared to chondrocytes that are predominantly generating catabolic factors contributing to ECM breakdown. Also, variations in data may arise depending on whether hip or knee articular cartilage is analyzed. In any case, the altered expression of miR-140 in OA cartilage makes sense from its reported functions in regulating chondrocyte differentiation and cartilage homeostasis as mentioned earlier in this review. It is therefore not surprising that a recent study has reported a chondroprotective effect by delivery of miR-140-enriched exosomes to rat knee joints following OA induction. 80 A number of independent studies showing increased levels of miR-483 and miR-146a in OA cartilage and the potential of targeting these miRNAs to modulate OA has already been discussed in this review. A recent study has also identified increased levels of miR-146a in peripheral mononuclear blood cells from OA patients at more progressive stages of disease. 172 Increased levels of miR-181a was found in OA facet joint cartilage while decreased levels were identified in knee OA cartilage. 138, 139 This again points to the possibility that miRNAs may have distinct functions in chondrocytes at different anatomical locations. Overexpression of miR-181a appears to be deleterious for facet cartilage, 138 yet whether or not the same is true for articular cartilage of the knee or hip remains to be determined.
A few studies have been carried out to measure circulating miRNA levels in patients with OA. Cuadra et al. found that a subset of 12 miRNAs were elevated in the plasma of patients with primary OA compared to non-diseased control specimens. 82 Interestingly, the inflammation-responsive miRNA already discussed in this review (miR-146a) was one of the upregulated miRNAs in this study. However, whether or not any of the identified miRNAs could be potential biomarkers for OA is not clear due to the relatively small sample size analyzed. Also, the amount of miRNAs analyzed in their array was quite low. Another study by Beyer et al. followed a larger cohort of patients, a percentage of which were identified as having severe hip or knee OA and measured miRNAs in the plasma of these patients. Here, let-7a was the only miRNA that emerged as a potential predictor for severe knee of hip OA. 173 While interesting, one drawback of the study was that plasma from knee and hip OA patients were analyzed together in one group. It is possible that different expression signatures may exist between knee and hip OA patients. Recently, a more controlled study was carried out in mice where circulating serum miRNAs were measured at specific time points following surgical induction of OA by destabilization of the medial meniscus or following intra-articular injection of bovine serum albumin (antigen-induced arthritis) in mice. 174 Although expected degradation patterns were observed in the knee joints of both arthritis models, no serum miRNAs were significantly dysregulated suggesting these may not represent useful biomarkers to distinguish early or progressive stages of arthritis.
Among the studies reporting differential expression of miRNAs in conditions of low bone mass and/or bone fractures, Wang et al. showed that expression levels of miR-214 were higher in human bone specimens from aged individual and that this miRNA negatively correlated with expression of bone formation markers BGLAP (osteocalcin) and ALP (alkaline phosphatase) in aged women and men with fractures. 105 Similarly, a more recent study showed an age-related elevation in levels of miR-214 in whole serum, serum exosomes and in bone specimens from post-menopausal women. 110 Furthermore, this increase in miR-214 concentration was accelerated in the elderly female group with low energy fractures compared to those without fractures. Together, these findings show that elevated miR-214 levels correlate with decreased bone mass/bone fragility in humans. This is a good example of how human clinical data has provided a strong rationale to justify approaches to target a miRNA in vivo. As described in the previous section, inhibition of miR-214 in mice does indeed appear to attenuate conditions associated with low bone mass.
A recent report has identified polymorphisms in two pri-miRNAs (miR-3679 and miR-4274) that are associated with an osteoporotic phenotype in humans. 175 Higher expression of these miRNAs was also identified in osteoporotic fractured bones of the hip. These findings justify further studies aimed at modulating expression of miR-3679 and/or miR-4274 in vivo to determine effects on bone mass.
A recent study identified serum miRNA signatures that were indicative of skeletal fractures in postmenopausal women with and without type II diabetes, 176 while another report identified a few differentiallyexpressed miRNAs in human osteoporotic hip bone specimens. 177 Yavropoulou et al. analyzed circulating miRNAs to identify potential biomarkers for osteoporosis and osteoporotic fractures. 178 Five miRNAs were significantly deregulated in the serum of patients with MicroRNAs IN ORTHOPAEDIC RESEARCH low bone mass compared with controls, two of which (miR-29a and miR-2861), have already been discussed in this review. In addition, low expression of miR-21 was found to be significant among women with low bone mass in addition to vertebral fractures.
Circulating serum levels of miRNAs were measured in male and female subjects with idiopathic and postmenopausal osteoporosis. 179 A set of 19 miRNAs were differentially regulated in these patients and, of these, eight miRNAs (including miR-140) could discriminate between the patients with and without lowtraumatic fractures. In addition, this study also revealed that some miRNAs, including miR-29b and miR-365, correlated well with bone turnover markers.
Interestingly, another recent study identified an association between miRNA polymorphisms (miR146a, miR-149, miR-196a2, miR-499) and osteoporotic vertebral compression fracture susceptibility in Korean postmenopausal women. 180 With respect to endochondral fracture healing, miRNA expression signatures have been monitored in rodent hind limbs at various times following fracture induction. One study reported miRNA expression patterns during early phases of fracture repair 181 while another report compared miRNA levels in bones following femoral fracture of adult or aged female mice. 182 Another recent study identified a miRNA signature in standard femoral healing fractures compared with non-healing fractures in rats at 14 days post-surgery. 183 Among the differentially-expressed miRNA, miR-140 and miR-181a/d were found to be significantly higher in the healing fractures. This finding makes sense because miR-140 and miR-181 are known to be highly expressed in hypertrophic cartilage tissue 131, 134 and endochondral fracture repair occurs via formation of a hypertrophic cartilage callus.
Intervertebral disc degeneration (IVDD) is the predominant cause of chronic low back pain, placing a heavy burden on the global healthcare system. The etiology of IVDD is currently attributed to the interaction between environmental and genetic factors. Genetic heredity is the major risk-factor for IVDD and is believed to cause more than 70% of cases. 184 Notably, expression profiling studies have identified a number of dysregulated miRNAs in human degenerated IVDs when compared to control specimens. [185] [186] [187] [188] Another study reported higher levels of miR-100 in human lumbar degenerated discs compared to traumatized, non-degenerated human specimens and that altered expression levels correlated with FGFR1. 189 A polymorphism in pre-miR-125a (Rs12976445) has been shown to result in a significant reduction in the amount of mature miR-125a by compromising its processing, thereby leading to less efficient inhibition of target genes. 190 This polymorphism has since been associated with the apoptotic state of nucleus pulposus cells and the risk of intervertebral disc degeneration in the Chinese population. 191 While a number of in vitro studies on human disc tissue suggest a role for specific miRNAs in the pathogenesis of IVVD, in vivo animal studies to determine the function and mechanism of miRNAs in IVDD are lacking.
Clearly, miRNAs are altered in many orthopaedic disease states. In most cases, it is difficult to determine if miRNA dysregulation is a major cause of the disease or a downstream consequence of the disease. As discussed in this review, cases exist where correcting the expression level of a miRNA in disease is effective in attenuating the conditions. In the absence of human in vivo data, one can obtain expression profiles of miRNAs from patient cells in vitro, or even from cells of healthy donors that have been treated with a disease-inducing agent. Analysis of miRNA expression profiles during developmental processes (e.g., in vitro chondrogenesis or osteogenesis assays) can also provide insights into whether or not specific miRNAs may regulate these processes. Whether the goal is to attenuate disease or to enhance tissue repair or regeneration, approaches to modulate the miRNA in vitro and in vivo must be utilized to determine functional outcome. The next section will discuss various methods that have been applied to modulate miRNA levels to better understand in vivo function.
APPROACHES TO MODULATE miRNA FUNCTION IN VIVO
As has been discussed in this review, a number of "orthopaedic tissue-associated" miRNA candidates have been identified by either expression profiling analysis (i.e., dysregulated miRNA expression in orthopaedic disease states) or by functional assays (i.e., miRNAs that can enhance chondrocyte or osteoblast anabolism in vitro). Efficient approaches are therefore required to modulate (over-express or inhibit) such candidate miRNAs in appropriate animal models to begin to better understand their functional role in vivo.
As mentioned previously, lentiviral-based strategies have been used to either over-express a pre-miRNA or an anti-miRNA sequence in vivo. This has been a popular approach to deliver the pre-miRNA or the anti-miRNA within rodent knee joints to examine the effects of miRNA modulation on OA progression, for example. While this is a reasonable first-step approach to decipher in vivo function in rodents, viral approaches are generally not considered to be safe for human clinical use (with perhaps the exception of adeno-associated virus). Another issue to consider is the efficiency of lentivirus penetration into skeletal tissues such as cartilage. None of the studies referenced in this review showed over-expression or inhibition of the miRNA of interest in situ in rodent cartilage following intra-articular injection of specific lentiviral constructs. 103, 121, 137, 157, 165 However, two of these studies did did show an up-regulation of the miRNA of interest following cartilage extraction and qPCR. 121, 157 To date, it is still challenging to carry out in situ hybridization for detection of miRNAs in vivo.
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However, other studies have demonstrated successful lentiviral uptake by chondrocytes in murine articular cartilage following intra-articular injection. For example, an Igf2 and GFP-expressing lentivirus was shown to penetrate murine articular cartilage resulting in subsequent protein over-expression. 192 It therefore appears that such viral constructs can indeed be taken up by chondrocytes in rodent articular cartilage. With that said, it would be still important for intra-articular viral-based miRNA modulation approaches that a control virus over-expressing a fluorescent marker be included in experiments to confirm cartilage uptake and, whenever possible, over-expression or knockdown of the miRNA of interest be confirmed by qPCR.
A more clinically-relevant approach to modulate miRNA expression and function is the use of either miRNA mimics or antagomirs. Mimics are small, chemically modified double-stranded RNAs that mimic the endogenous miRNA, thereby creating a gain-offunction scenario. Modified miRNAs are much more stable than natural miRNAs and are not cleared as readily from the body; however there can be issues with accessibility to the target cell. 193 Common modifications that reduce nuclease sensitivity include introduction of phosphorothioate bonds, formation of locked nucleic acids (i.e., a modified ribose moiety with an extra bridge connecting the 2 0 oxygen and 4 0 carbon), 5 0 O-methylation of the passenger strand, or 2 0 O-methyl modification of ribose which, in addition to increasing stability, can also decrease activation of the innate immune response. Antagomirs, which can be chemically modified similar to that of mimics, are single stranded RNA molecules designed to bind tightly to endogenous miRNAs, thereby resulting in miRNA loss-of-function.
Within oncology, the first miRNA-based therapy approach, MRX34, entered clinical testing in 2013. 194 This synthetic mimic was designed to restore levels of miR-34a which are known to decrease in many tumor types. A liposome-based approach was used to deliver MRX34 to attempt to modulate p53/wnt cellular pathways; however, this clinical trial has since been terminated.
As listed in the clinicaltrials.gov website, other miRNA therapies are currently under clinical assessment, including miravirsen, a phosphorothioated antagomir designed to bind to and inhibit the function of miR-122, a miRNA essential for replication of hepatitis C virus (HCV). Participants are currently being recruited for a Phase I clinical trial to test the safety and pharmacokinetics of MRG-106, a miR-155 antagomir, for the treatment of cutaneous T-cell lymphoma. A Phase I trial has recently been completed to test the safety and tolerability of MRG-201, a miR-29 mimic. The long-term goal of these studies is to determine if application of this mimic can limit the formation of scar tissue in certain diseases given reports that miR-29 can decrease expression of collagen and other components involved in scar formation.
The first testing of "TargomiRs" has been completed in a Phase I study with the goal of delivering miR-16 mimics as a means to treat certain cancers. TargomiRs consist of nonliving bacterial minicells (i.e., nanoparticles) and function as a leak resistant micro-carrier for delivery of the mimic. These micro-carriers, which are injected intravenously, are also designed to target EGFR-expressing cancer cells. It will be interesting to see if this type of delivery technology will be effective in vivo.
Certainly, optimization of miRNA delivery approaches is a critical factor if the goal is to target specific tissues or cell types to combat disease. Targeting cells in tissues such as bone and cartilage presents challenges given the complex nature of the extracellular matrix consisting of dense networks of mineral, collagen and/or highly-charged proteoglycans. With that said, a specific peptide sequence attached to cationic liposomes was generated to deliver small RNAs to bone-formation surfaces. 195 This strategy was apparently successful in delivering miR-214 antagomirs to bone in rodents since induced bone loss was attenuated. 105 However, this group has since claimed to have developed an improved delivery strategy to specifically target osteoblasts. Following a highthroughput screening approach, an oligonucleotide aptamer was selected by its ability to specifically bind to osteoblasts. This aptamer was conjugated to lipid nanoparticles (LNPs) encapsulating an siRNA against Plekho1 and showed enhanced bone anabolism following injection into ovariectomized rats. 196 It is expected that specific miRNA mimics or antagomirs could also be delivered to osteoblasts by these aptamer-functionalized LNPs. Another recent study also reported development of an osteoblast-targeting peptide conjugated to polyurethane nanomicelles as a means to deliver antagomir-214 to bone. 197 Encouragingly, increased bone formation was found following injection of these nanoparticles into ovariectomized osteoporotic mice.
With respect to cartilage tissue, cationic peptideconjugated nanoparticles complexed to NF-kB siRNA were delivered by intra-articular injection into knee joints following joint loading, resulting in decreased apoptosis and reactive synovitis. 198 Importantly, these nanoparticles were found to penetrate cartilage tissue and remain within chondrocyte lacunae for at least 2 weeks. These peptide-nanocomplexes could also be used to deliver miRNA mimics or antagomirs as well and open up new opportunities in the field of cartilage repair or protection strategies.
In addition to synthetic approaches to deliver miRNAs, a lot of interest is currently focused on the therapeutic potential of utilizing extracellular vesicles (EVs) as delivery vehicles. 199, 200 EVs have been reported to contain specific protein cargo, lipids, RNA transcripts, miRNAs and DNA, and can function as intercellular communicators by transferring their contents between cells. 201 EVs can be divided into two classes, exosomes and microvesicles (MVs). Exosomes are released through the fusion of multivesicular bodies with the plasma membrane and exocytosis and are $40-100 nm in diameter. MVs are plasma membrane-derived and are shed as a result of budding and fission of the plasma membrane and are larger ($100-1,000 nm in diameter). Recently, more attention has been directed to the use of exosomes as therapeutic agents. There have been many reports suggesting that exosomes derived from MSCs are the principal therapeutic agent underpinning the regenerative potential of these cells. 202 Already discussed in this review, a recent study has shown that synovial MSC-derived exosomes enriched in miR-140 confers a chondroprotective effect when injected in rat knee joints following OA induction. 80 MSC-derived exosomes were also found to promote fracture healing in a mouse model. 203 Although miRNAs were not analyzed in this study, the authors suggest that bone repair may be mediated, in part, by specific miRNAs in these exosomes. As also mentioned previously in this review, a study by Sun et al. 111 showed that osteoclast-derived exosomes enriched in miR-214 could be transferred to osteoblasts to inhibit bone formation. These are just some examples of the research efforts currently underway to begin to decipher how effective naturally-produced exosomes may be as therapeutic miRNA/siRNA delivery vehicles to treat orthopaedic conditions. It is anticipated that this field will grow rapidly over the coming years as we learn more about the mechanisms controlling exosome generation, why different cell types generate exosomes containing distinct protein or oligonucleotide contents as well as how to manipulate exosome contents to maximize therapeutic benefit.
CONCLUSIONS AND PERSPECTIVES
We have discussed a number of miRNAs in this review that could be potentially attractive candidates to treat some human orthopaedic conditions such as OA, osteoporosis or bone fractures. Clearly, improvements in chemical design and delivery methods will be critical factors to maximize sensitivity and specificity of miRNA mimics or antagomirs. Also, determining the stability and duration of action of therapeutic miRNAs will be important when dealing with acute versus chronic disease. As most orthopaedic diseases are largely nonlethal, evidence to confirm in vivo safety will also be essential. Furthermore, it may be that modulating expression and function of multiple miRNAs, as opposed to only one miRNA, could be more effective in treating complex diseases. For example, a combined approach to modulate miRNAs that can ameliorate inflammation with miRNAs that can enhance anabolism in chondrocytes could be an effective strategy to treat OA. Similarly, strategies to enhance miRNAs known to negatively affect osteoclast function combined with miRNAs that activate osteoblasts could be investigated as a means to enhance bone formation.
Clearly, the interesting aspect of miRNA function is the intricate sophistication and finesse of gene regulation. Taking advantage of the fact that miRNAs can fine-tune the expression of multiple genes and cellular pathways, they could, in some cases, be more useful tools than siRNA within the context of more complex diseases to target molecular "interactomes." However, a more thorough understanding of how miRNAs regulate the transcriptome and proteome in different cell types, in addition to determining off target effects, will also be critical before translation into clinical use.
Importantly, significant efforts are being directed toward quantifying the relationship between miRNAs and target expression levels in mammalian cells. 204 With such knowledge, opportunities arise to perform forward engineering of synthetic miRNA circuits to incorporate post-transcriptional control systems in cells. For example, cells may be engineered to sense changes in specific proteins (i.e., elevated levels of an inflammatory cytokine or a catabolic enzyme) resulting in specific miRNA switches. Such programmed protein-responsive miRNA switches may aid in restoring homeostasis of dysregulated pathways in diseases such as OA. Alternatively, a cell may be engineered to sense altered levels of specific miRNAs (indicative of a specific disease state, for example) that will then trigger a desired response to attempt to combat disease. 205 The drive in merging systems biology and synthetic biology approaches to engineer new or desired functions in cells will undoubtedly continue at a fast pace and will become more sophisticated as we understand more about the intricacies of how miRNAs regulate cellular networks. 206, 207 
